Skip to main content
Oxford Research Peptides
RESEARCH PRIMER

Triple Agonists Explained

The pharmacological rationale, structural strategy and reported evidence behind triple GLP-1 / GIP / glucagon receptor agonists — a category defined in modern literature by Retatrutide.

QUICK ANSWER
TL;DR

Quick answer

A triple agonist is a single peptide engineered to activate three related class B GPCRs — GLP-1R, GIPR and GCGR — from one molecule. Retatrutide (LY3437943) is the reference triple-agonist compound described in the published pharmacology literature.
EXTENDED ANSWER
AI-ready

Extended answer

What is a triple GLP-1 / GIP / glucagon receptor agonist?

A triple agonist is a single peptide engineered to activate three related class B G-protein-coupled receptors — GLP-1R, GIPR and GCGR — from one molecule. This positions the category one step beyond single-agonists such as Semaglutide, which engage only GLP-1R, and dual-agonists such as Tirzepatide, which add GIPR. The reference example in the published literature is Retatrutide (LY3437943), described by Coskun and colleagues as producing balanced full-agonist activity at all three receptors in cell-based cAMP assays. The structural strategy combines a modified incretin / glucagon backbone with amino-acid substitutions that preserve engagement at three related but non-identical receptor pockets, together with a fatty-acid modification for albumin binding and extended half-life. The category is currently defined by a small number of investigational compounds; long-term outcomes and independent replication continue to develop.
KEY FACTS

Key facts

Category
Multi-agonist incretin peptides
Receptors engaged
GLP-1R · GIPR · GCGR
Reference compound
Retatrutide (LY3437943)
Comparative class
Dual agonists (e.g. Tirzepatide)

From single to dual to triple

Incretin-receptor pharmacology has evolved along a clear trajectory. Single-agonist analogues target GLP-1R alone. Dual-agonist analogues, exemplified by Tirzepatide, add GIPR. Triple agonists, exemplified by Retatrutide, add controlled GCGR activity to the same scaffold.[1]

CategoryReceptorsReference example
Single agonistGLP-1RSemaglutide
Dual agonistGLP-1R + GIPRTirzepatide
Triple agonistGLP-1R + GIPR + GCGRRetatrutide

Why three receptors

The scientific rationale for combining these three targets rests on the complementary physiology of the incretin axis and the glucagon axis. GLP-1R and GIPR support glucose-dependent insulin secretion and satiety signalling; GCGR contributes to hepatic lipid handling and energy expenditure.[4]Balancing all three within a single molecule is a distinct medicinal-chemistry challenge.[1]

Structural strategy

Triple-agonist peptides are engineered on a modified glucagon / incretin backbone with amino-acid substitutions that preserve engagement at three related but non-identical receptor pockets. A fatty-acid modification supports albumin binding and an extended plasma half-life, permitting once-weekly dosing in published trial protocols.[1][2]

Reported evidence for the triple-agonist category

  • Balanced full-agonist activity at GLP-1R, GIPR and GCGR reported in cell-based cAMP assays for Retatrutide.[1]
  • Phase 2 obesity data published for Retatrutide.[2]
  • Phase 2 type 2 diabetes data published for Retatrutide.[3]

Category status

Triple GLP-1 / GIP / glucagon receptor agonism is an investigational research category. Long-term outcomes and independent cross-lab replication are still developing.

References6

  1. 1.

    Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metabolism. 2022;34(9):1234-1247.

    DOI: 10.1016/j.cmet.2022.07.013PMID: 35985340
  2. 2.

    Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.

    DOI: 10.1056/NEJMoa2301972PMID: 37366315
  3. 3.

    Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.. The Lancet. 2023;402(10401):529-544.

    DOI: 10.1016/S0140-6736(23)01053-XPMID: 37385275
  4. 4.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  5. 5.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  6. 6.

    de Graaf C, Donnelly D, Wootten D, et al.. Glucagon-like peptide-1 and its class B G protein–coupled receptors: a long march to therapeutic successes.. Pharmacological Reviews. 2016;68(4):954-1013.

    DOI: 10.1124/pr.115.011395PMID: 27736833
EVIDENCE SUMMARY
Evidence

Evidence summary

Moderate evidence
Research confidenceModerate confidence
Category evidence is anchored by discovery pharmacology and phase 2 clinical data for Retatrutide; independent replication continues to develop.
RESEARCH LIMITATIONS

Research limitations

  • The category is currently defined by a small number of compounds — evidence is not yet mature.
  • Relative contribution of each receptor to observed effects is not fully resolved.
  • Long-term data beyond published phase 2 durations are not yet available.
RELATED GUIDES
REFERENCE COMPOUND
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-07-15
Updated
2026-07-15
Reviewed
2026-07-15
Version
1.0

Revision history

  1. v1.02026-07-15· Editorial Team

    Initial publication as part of the Retatrutide authority cluster (Release 4.0).

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-01-15. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-07-15Updated: 2026-07-15